Across TCGA pan-cancer cohorts, CXorf66 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CXorf66’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CXorf66 RNA is repressed in tumor relative to normal tissue. In most cancer types CXorf66 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, CHOL, and KIRC are the cancer types where CXorf66 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CXorf66 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−0.289	<.001	7	view →
CHOL	All	All	−0.305	<.001	4	view →
KIRC	Male	All	−0.007	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CXorf66 RNA expression & survival · all CXorf66 data types